MODIFIED RELEASE OF 4-METHYL-3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]-N-5-(4-METHYL-1H-IMIDAZOL-1-YL)-3-(TRIFLUOROMETHYL)PHENYL] BENZAMIDE SOLUBILIZED USING ORGANIC ACIDS

MODIFIED RELEASE OF 4-METHYL-3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]-N-5-(4-METHYL-1H-IMIDAZOL-1-YL)-3-(TRIFLUOROMETHYL)PHENYL] BENZAMIDE SOLUBILIZED USING ORGANIC ACIDS

Soluble pharmaceutical compositions of amorphous nilotinib or a pharmaceutically acceptable salt thereof were invented using one or more organic acids that function as a solubilizing agent, increasing the bioavailability of nilotinib and supressing the food effect associated with certain composition...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: KAVIMANDAN NIKHIL JAVANT, LI SHOUFENG, KUMAR SARAN, LU ENXIAN
Format: Patent
Sprache:eng ; fre
Schlagworte:
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Soluble pharmaceutical compositions of amorphous nilotinib or a pharmaceutically acceptable salt thereof were invented using one or more organic acids that function as a solubilizing agent, increasing the bioavailability of nilotinib and supressing the food effect associated with certain compositions of nilotinib. The pharmaceutical compositions are in th form of solid oral dosage forms, including capsules and tablets.